OncoMatch/Clinical Trials/NCT07020806
[68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic/Advanced Invasive Lobular Breast Cancer (LBC)
Is NCT07020806 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies [68Ga]Ga DOTA-5G for metastatic lobular breast carcinoma.
Treatment: [68Ga]Ga DOTA-5G — This is a prospective study using \[68Ga\]Ga DOTA-5G PET/CT imaging in patients diagnosed with metastatic/advanced invasive lobular breast cancer (LBC).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Breast Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Lab requirements
Blood counts
Absolute neutrophil count (ANC) ≥ 1000 cells/mm3, Platelet count ≥ 100,000/mm3, Hemoglobin ≥ 8 g/dL
Kidney function
eGFR >60 mL/min/1.73m*2
Liver function
AST, ALT, alkaline phosphatase ≤ 5 times upper limit of normal (ULN), Total bilirubin ≤ 2 times ULN
Hematologic parameters defined as: Absolute neutrophil count (ANC) ≥ 1000 cells/mm3, Platelet count ≥ 100,000/mm3, Hemoglobin ≥ 8 g/dL. Blood chemistry levels defined as: AST, ALT, alkaline phosphatase ≤ 5 times upper limit of normal (ULN), Total bilirubin ≤ 2 times ULN, eGFR >60 mL/min/1.73m*2
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California Davis · Sacramento, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07020806 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 89 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages